“The risk of side effects, particularly those affecting the bowel, are key considerations for both clinicians and patients in the decision-making in the treatment of prostate cancer,” said Dr. Peter Chung, radiation oncologist at Princess Margaret and assistant professor, Department of Radiation Oncology, University of Toronto. “Our team at Princess Margaret looks forward to using SpaceOAR hydrogel as indicated as part of our ongoing efforts to bring patients the most effective treatment options while reducing the side effects of radiation therapy.”
About SpaceOAR Hydrogel
Radiation therapy in the treatment of prostate cancer can cause unintended radiation injury to adjacent healthy tissue (organs at risk). This injury can lead to a range of bowel, urinary and sexual symptoms that can affect patient health and quality of life during radiotherapy, and for years afterward. SpaceOAR hydrogel is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space, SpaceOAR hydrogel reduces the radiation dose delivered to the anterior rectum.
Ad Statistics
Times Displayed: 113248
Times Visited: 6741 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
SpaceOAR hydrogel is licensed in Canada, cleared by the U.S. Food and Drug Administration and is currently being used in the majority of leading cancer centers in the United States. It is CE marked in the European Union and approved in Australia. See the Instructions for Use for complete information on potential risks, warnings and precautions.
About Augmenix, Inc.
Augmenix, Inc. is a privately held company based in the Boston area and focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. Focusing initially on protection during prostate radiation therapy, Augmenix next-generation products will address spacing and marking applications throughout the body to improve radiotherapy and interventional oncology procedure outcomes. SpaceOAR is a registered trademark of Augmenix, Inc. More information about Augmenix and the SpaceOAR hydrogel can be found at http://www.Augmenix.com.
About Princess Margaret Cancer Centre, University Health Network
The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to www.theprincessmargaret.ca or www.uhn.ca.
